3 Pharmaceuticals Company, Crop Protection Company and Cement Maker Stocks With a Strong Future Roadmap: Ajanta Pharma, Insecticides India and Star Cement
- November 16, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Ajanta Pharma, Insecticides India and Star Cement: ROE of 11.4% to 23.3% and FY22 to FY26 revenue CAGR of 9.3% to 13.9%. Prices as of 13 Nov 2026.
Quick Answer
The three pharma, crop care and cement stocks to watch are Ajanta Pharma, Insecticides India and Star Cement. Their return on equity ranges from 11.4% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.3% to 13.9%. Ajanta Pharma has the highest return on equity at 23.3%, while Star Cement has the fastest revenue growth at 13.9% a year. Prices are based on the 13 November 2026 close, and this article is educational, not investment advice.
Pharma, crop care and cement stocks bring together companies with a visible plan for the years ahead. Ajanta Pharma, Insecticides India and Star Cement cover a pharmaceuticals company, a crop protection company and a cement maker.
This list covers three pharma, crop care and cement stocks with complete current figures: Ajanta Pharma, Insecticides India and Star Cement. Every figure comes from the latest reported financials and the 13 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma, Crop Care and Cement Stocks?
Pharma, crop care and cement stocks are listed companies that make and sell branded medicines in India and abroad, make and sell crop protection products to farmers, and make cement for homes, roads and infrastructure. Their earnings depend on medicine demand, farm activity and construction activity.
Pharma, Crop Care and Cement Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Ajanta Pharma | 3,284 | 41,241 | 36.3 | 36.0 | 23.3 | 0.06 |
| Insecticides India | 539.95 | 1,507 | 12.0 | 21.9 | 11.4 | 0.13 |
| Star Cement | 176.06 | 6,481 | 17.7 | 29.6 | 12.3 | 0.19 |
On valuation, Insecticides India and Star Cement trade at a P/E below the industry P/E, while Ajanta Pharma trades above it, which reflects the growth the market already expects. Readers comparing pharma, crop care and cement stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Pharma, Crop Care and Cement Stocks Have a Strong Roadmap in India?
Pharma, crop care and cement stocks have a strong roadmap in India because growing demand for quality medicines, wider use of crop care inputs and heavy spending on housing and roads keep widening the market for these companies.
- Pharmaceuticals. Patients need quality medicines.
- Crop protection. Farmers protect their crops.
- Cement. Roads and homes need cement.
Why Ajanta Pharma Features Among These Pharma, Crop Care and Cement Stocks
Among the pharma, crop care and cement stocks on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.
Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%.
In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.
Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
What to watch: Monitor the pace of new launches in branded markets and the momentum in the United States generics business.
Why Insecticides India Features Among These Pharma, Crop Care and Cement Stocks
Among the branded medicine, pesticide maker and building material shares on this list, Insecticides India is a Delhi-based crop protection company that makes and sells insecticides, herbicides and fungicides to farmers through a wide network of dealers and distributors.
Revenue rose from Rs 1,508 crore in FY22 to Rs 2,152 crore in FY26, a compound annual growth rate of 9.3%. Net profit grew from Rs 107 crore in FY22 to Rs 139 crore in FY26, which works out to a compound annual growth rate of 6.7%.
The company has a return on equity of 11.4%, a debt to equity ratio of 0.13 and a market capitalisation of Rs 1,507 crore. The stock trades at a P/E of 12.0, below the industry P/E of 21.9.
Roadmap: The company is launching new formulations and growing its own brands, which supports better margins. Rising demand for crop protection from Indian farmers supports steady volumes.
What to watch: Follow monsoon trends, new product launches and technical raw material costs.
Why Star Cement Features Among These Pharma, Crop Care and Cement Stocks
Among the three companies on this list, Star Cement is a leading cement maker in India’s North East, producing cement at plants in Meghalaya and Assam and selling across the region and in eastern India.
The company has a return on equity of 12.3%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 6,481 crore. The stock trades at a P/E of 17.7, below the industry P/E of 29.6.
Revenue rose from Rs 2,255 crore in FY22 to Rs 3,796 crore in FY26, a compound annual growth rate of 13.9%. Net profit grew from Rs 247 crore in FY22 to Rs 390 crore in FY26, which works out to a compound annual growth rate of 12.2%. In the June 2026 quarter, revenue grew 4.1% year on year to Rs 951 crore.
Roadmap: The company is expanding capacity and widening its reach in eastern India, while infrastructure and housing spending in the North East supports demand. Its strong regional position helps pricing.
What to watch: Follow regional cement prices, capacity expansion and fuel and freight costs.
Ajanta Pharma vs Insecticides India vs Star Cement on Key Financials
The table below sets the three pharma, crop care and cement stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Ajanta Pharma | 3,457 | 5,625 | 12.9% | 1,056 | 18.8% |
| Insecticides India | 1,508 | 2,152 | 9.3% | 139 | 6.5% |
| Star Cement | 2,255 | 3,796 | 13.9% | 390 | 10.3% |
Ajanta Pharma posts the highest return on equity in this group at 23.3%. Ajanta Pharma has the largest FY26 revenue at Rs 5,625 crore, and Star Cement shows the fastest revenue growth with a 13.9% compound annual rate. A useful habit with pharma, crop care and cement stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Pharma, Crop Care and Cement Stocks
Every theme carries risks that deserve a check before any decision. For these pharma, crop care and cement stocks, the main points are: Long-term branded medicine, pesticide maker and building material shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Season and monsoon. Crop protection sales follow rain and pest cycles.
- Raw material costs. Ingredient and packaging prices can move margins.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma, crop care and cement stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma, Crop Care and Cement Stocks
Pharma, crop care and cement stocks suit investors who prefer to study business strength before price moves. Ajanta Pharma, Insecticides India and Star Cement each have a clear plan to grow. Based on the 13 November 2026 close, Ajanta Pharma trades at Rs 3,284, Insecticides India at Rs 539.95 and Star Cement at Rs 176.06.
Download the Univest iOS App or Univest Android App to track pharma, crop care and cement stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma, crop care and cement stocks?
Ans. Pharma, crop care and cement stocks are listed companies that make and sell branded medicines in India and abroad, make and sell crop protection products to farmers, and make cement for homes, roads and infrastructure. Their earnings depend on medicine demand, farm activity and construction activity. This list looks at three of them, Ajanta Pharma, Insecticides India and Star Cement, using reported FY22 to FY26 financials and the 13 November 2026 closing prices.
Which pharma, crop care and cement stocks are covered in this list?
Ans. This list covers Ajanta Pharma, Insecticides India and Star Cement. Based on the 13 November 2026 close, Ajanta Pharma traded at Rs 3,284, Insecticides India at Rs 539.95 and Star Cement at Rs 176.06. Their return on equity ranges from 11.4% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.3% to 13.9%.
Why do pharma, crop care and cement stocks have a strong future roadmap in India?
Ans. Pharma, crop care and cement stocks have a strong roadmap in India because growing demand for quality medicines, wider use of crop care inputs and heavy spending on housing and roads keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Patients need quality medicines. Crop protection. Farmers protect their crops. Cement. Roads and homes need cement. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Ajanta Pharma performed financially?
Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
How has Insecticides India performed financially?
Ans. Revenue rose from Rs 1,508 crore in FY22 to Rs 2,152 crore in FY26, a compound annual growth rate of 9.3%. Net profit grew from Rs 107 crore in FY22 to Rs 139 crore in FY26, which works out to a compound annual growth rate of 6.7%. The company has a return on equity of 11.4%, a debt to equity ratio of 0.13 and a market capitalisation of Rs 1,507 crore. The stock trades at a P/E of 12.0, below the industry P/E of 21.9. Looking ahead, the company is launching new formulations and growing its own brands, which supports better margins. Rising demand for crop protection from Indian farmers supports steady volumes.
How has Star Cement performed financially?
Ans. Revenue rose from Rs 2,255 crore in FY22 to Rs 3,796 crore in FY26, a compound annual growth rate of 13.9%. Net profit grew from Rs 247 crore in FY22 to Rs 390 crore in FY26, which works out to a compound annual growth rate of 12.2%. In the June 2026 quarter, revenue grew 4.1% year on year to Rs 951 crore. The company has a return on equity of 12.3%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 6,481 crore. The stock trades at a P/E of 17.7, below the industry P/E of 29.6. Looking ahead, the company is expanding capacity and widening its reach in eastern India, while infrastructure and housing spending in the North East supports demand. Its strong regional position helps pricing.
What risks should investors check before buying pharma, crop care and cement stocks?
Ans. Investors should check a few risks before buying pharma, crop care and cement stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Season and monsoon. Crop protection sales follow rain and pest cycles. Raw material costs. Ingredient and packaging prices can move margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma, crop care and cement stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 13 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.